Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Withdrawn 1Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4Other hematologic neoplasm 3Myeloid 3Lymphoid 3Classical hematology 1

Conditions

Myelodysplastic Syndromes 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Leukemia, Myeloid, Acute 9Leukemia 9Hematologic Neoplasms 7Lymphoma, Non-Hodgkin 6Lymphoma 6Multiple Myeloma 4Primary Immunodeficiency Diseases 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Immunoproliferative Disorders 3Immune System Diseases 3Hodgkin Disease 3Cytopenia 3Anemia, Aplastic 3Thalassemia 2Osteopetrosis 2Neoplasm, Residual 2Neoplasm Metastasis 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hemoglobinopathies 2Fanconi Anemia 2Cytokine Release Syndrome 2Breast Neoplasms 2Anemia, Sickle Cell 2Anemia, Diamond-Blackfan 2Anemia 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Thymoma 1

Interventions

Dexamethasone 808Bortezomib 446Lenalidomide 430Cyclophosphamide 336Melphalan 250Calcium Dobesilate 236daratumumab 217pomalidomide 201carfilzomib 181fludarabine phosphate 131Thalidomide 121fludarabine 118Peripheral Blood Stem Cell Transplantation 117Filgrastim 111ixazomib 85Mycophenolic Acid 85Granulocyte Colony-Stimulating Factor 84Busulfan 83Whole-Body Irradiation 80Tacrolimus 75dexamethasone acetate 74Cyclosporine 67Prednisone 64dexamethasone 21-phosphate 63isatuximab 62elotuzumab 60auricularum 57Antilymphocyte Serum 55belantamab mafodotin 54Etoposide 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Multiple Myeloma × AP 1903 reagent × Clear all
NCT02477878 2022-07-12

Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant

Bellicum Pharmaceuticals

Phase 1 Active not recruiting
10 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Hematologic Neoplasms

NCT03958656 2021-09-09

T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
13 enrolled 15 charts
Plasma cell

Multiple Myeloma

NCT02786485 2020-10-05

Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT

Bellicum Pharmaceuticals

Phase 1 Withdrawn
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hematologic Diseases, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Hematologic Neoplasms

NCT01875237 2019-07-16

Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

M.D. Anderson Cancer Center

Phase 1/2 Terminated
3 enrolled 15 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡